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bjectives The purpose of this study was to assess the frequency of very late stent thrombosis
VLST) after stenting with bare-metal stents (BMS) and drug-eluting stents (DES) for ST-segment
levation myocardial infarction (STEMI).
ackground Stent thrombosis occurs more frequently after stenting for STEMI than after elective
tenting, but there are little data regarding VLST.
ethods Consecutive patients (n  1,463) who underwent stenting for STEMI were prospectively
nrolled in our database. BMS were implanted exclusively from 1995 to 2002, and DES and BMS
ere implanted from 2003 to 2009. Follow-up was obtained at 1 to 15 years.
esults BMS patients (n  1,095) were older and had more shock, whereas DES patients (n  368)
ad more diabetes and smaller vessels. Stent thrombosis occurred in 107 patients, of which 42 were
LST (1 year). Stent thrombosis continued to increase to at least 11 years with BMS and to at least
.5 years with DES. Stent thrombosis rates with BMS versus DES were similar at 1 year (5.1% and
.0%, respectively) but increased more with DES after the ﬁrst year (1.9%/year vs. 0.6%/year, respec-
ively). Landmark analysis (1 year) found DES had a higher frequency of VLST (p  0.001) and rein-
arction (p  0.003). DES was the only signiﬁcant independent predictor of VLST (hazard ratio: 3.79,
5% conﬁdence interval: 1.64 to 8.79, p  0.002).
onclusions VLST after primary PCI for STEMI occurs with relatively high frequency to at least 11
ears with BMS and to at least 4.5 years with DES. Very late stent thrombosis and reinfarction
1 year) were more frequent with DES. New strategies are needed to manage this problem.
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31he use of coronary stents has become the preferred therapy
ith primary percutaneous coronary intervention (PCI) for
T-segment elevation myocardial infarction (STEMI) (1,2).
nfortunately, stent thrombosis (ST) has been a more frequent
omplication after stenting for STEMI than after elective
tenting with both drug-eluting stents (DES) and bare-metal
tents (BMS) (3–5). There is concern that very late stent throm-
osis (VLST) (1 year) might be more frequent with DES than
MS, because of increased frequency of late stent malapposition
nd poor healing of DES after primary PCI (6–8).
See page 39
Most randomized trials comparing DES and BMS with
rimary PCI for STEMI have shown reduced target vessel
evascularization with DES without an increased incidence of
T (9–13). Unfortunately, most of these studies have been
imited by either small numbers of patients or lack of long-term
ollow-up.
We have prospectively enrolled STEMI patients treated
ith primary PCI into an ongoing database dating back to the
arly use of stents with STEMI in 1995. This has allowed for
ong-term follow-up and has provided a unique opportunity to
valuate the frequency of VLST. The purpose of this study is
Table 1. Baseline Variables by Stent Type
BMS
(n  1,095
DES
(n  368)
p Valuen % n %
Clinical variables
Age 70 yrs 269 24.6% 70 19.0% 0.029
Female 351 32.1% 104 28.3% 0.17
Diabetes 150 13.7% 75 20.4% 0.002
Prior infarction 129 11.8% 39 10.6% 0.54
Prior bypass surgery 58 5.3% 11 3.0% 0.071
Current smoker 569 52.0% 192 52.2% 0.94
Anterior infarction 372 34.0% 151 41.0% 0.014
Cardiogenic shock 89 8.1% 13 3.5% 0.003
Angiographic and procedural variables
Infarct artery
Left main/left anterior descending 368 33.6% 149 40.5% 0.066
Circumﬂex artery 143 13.1% 48 13.0%
Right coronary artery 552 50.4% 167 45.4%
Saphenous vein graft 32 2.9% 4 1.1%
3-vessel coronary disease 268 24.5% 69 18.8% 0.024
Ejection fraction 40% 211 19.3% 64 17.4% 0.35
TIMI ﬂow grade 2–3 pre-PCI 267 24.4% 109 29.6% 0.047
TIMI ﬂow grade 3 post-PCI 1,044 95.3% 351 95.4% 0.30
GP IIb/IIIa platelet inhibitor 730 66.7% 251 68.2% 0.59
Balloon size (stent size) 2.75 mm 203 18.5% 107 29.1% 0.0001
Multiple stents 235 21.5% 108 29.3% 0.002
BMS bare-metal stent(s); DES drug-eluting stent(s); GP glycoprotein; TIMI ThrombolysisbIn Myocardial Infarction.o evaluate the frequency of VLST and its consequences, after
rimary PCI with stenting with both BMS and DES.
ethods
tudy population. The study population consists of 1,463
onsecutive patients with STEMI treated with primary PCI at
ur institution from 1995 through 2009 who received a stent
nd who did not have STEMI due to ST. Patients were
ncluded in our registry if they had electrocardiographic ST-
egment elevation 1 mm in 2 contiguous leads or new left
undle branch block, symptoms of12-h duration (12 h for
ersistent ischemic symptoms or hemodynamic compromise),
nd were treated with primary PCI. Patients were divided into
groups depending on whether they received BMS (n 
,095) or DES (n  368).
reatment protocol. Patients were treated with contemporary
tandards of care for primary PCI. In the early years this
ncluded aspirin, unfractionated heparin, and glycoprotein
Ib/IIIa platelet inhibitors, and in very recent years aspirin and
ivalirudin were used, usually
ithout glycoprotein IIb/IIIa
latelet inhibitors. Ticlopidine (in
he early years) or clopidogrel
ere given immediately before or
t the time of PCI. BMS were
sed exclusively from 1995 to
002, and DES or BMS were
sed from 2003 to 2009 at the
perator’s discretion. In 368 pa-
ients who received DES, 326 re-
eived first-generation DES
sirolimus- or paclitaxel-eluting
tents), and 42 received second-
eneration stents (everolimus-
nd zotarolimus-eluting stents).
ata collection and clinical follow-up. Patients were enrolled
rospectively into the database from 1995 through 2009.
rocedural data were assessed and entered by the interventional
ardiologist at the time of the PCI. Medical records for each
atient were reviewed to identify all readmissions for acute
oronary syndromes and all readmissions resulting in mortality.
tent thrombosis and myocardial infarction were identified
ccording to the definitions outlined in the following text.
eaths were also sought through the social security death
ndex, in which case the cause of death was determined by
eath certificates. All deaths, cardiac versus noncardiac deaths,
einfarctions, and all stent thromboses were adjudicated by at
east 1 of 3 investigators (B.B., T.S., and M.C.).
eﬁnitions and data analyses. ST was defined as definite or
robable ST according to the Academic Research Consortium
efinition (14). Definite ST occurred when there was an acute
oronary syndrome with angiographic confirmation of throm-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
VLST  very late stent
thrombosisus within the stent with partial or total occlusion of the stent.
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32robable ST occurred when there was an infarct in the territory
f the stented vessel without angiographic confirmation or
hen there was unexplained sudden death within 30 days.
n-hospital reinfarction was defined as occurring when there
ere recurrent ischemic symptoms associated with re-elevation
f the cardiac markers or documented occlusion of the infarct
rtery. Post-hospital reinfarction was defined as occurring
hen there was a repeat hospital admission for ischemic
ymptoms associated with elevation of the cardiac markers. All
eaths were categorized as cardiac or noncardiac.
tatistical analyses. Statistical comparisons of categorical vari-
bles were performed with the chi-square or Fisher exact test,
s appropriate. Two-sided Student t tests were used for
omparing continuous variables. Late clinical outcomes were
ssessed by Kaplan-Meier estimates and compared with log-
ank statistics. Multivariable analyses of predictors of late
ardiac outcomes were performed with Cox proportional haz-
rds regression models. All clinical and angiographic and
rocedural variables in Table 1 were entered into the Cox
egression models, and backward elimination at alpha  0.05
as used to select significant predictors. Type of stent (DES vs.
MS) was retained in all the models. To avoid excluding
atients from the analyses who had missing evaluations of
jection fraction, an indicator of ejection fraction missing/not
issing was also included. To allow comparisons between
Figure 1. Kaplan-Meier Estimates of ST Rates After Primary PCI With BMS
This ﬁgure compares cumulative stent thrombosis (ST) rates (Academic Resear
stents (DES) used with primary percutaneous coronary intervention (PCI) for ST
sively from 1995 to 2002, whereas BMS and DES were implanted from 2003 to 2009ES and BMS, which had different durations of follow-up,
aplan-Meier curves were compared out to 4.5 years.
Because stent type (DES or BMS) was not randomly
ssigned, propensity analyses by covariate adjustment were
mployed (15). Logistic regression was used to calculate a
ropensity score for each patient, and balance of the stent type
redictors was assessed within each quintile of the score.
ecause all stents were BMS before 2003, the propensity score
as set equal to 0 (i.e., 0 probability of DES) for all procedures
erformed before 2003. The propensity score and any of its
redictors that were not balanced between BMS and DES
ithin every score quintile were included in Cox regression
odels, along with the variables selected by backward elimi-
ation described in the preceding text. Analyses were con-
ucted on the entire set of data (1995 to 2009) and on the
ubset during which both BMS and DES were being used
2003 to 2009). All analyses were performed with SPSS
SPSS, Inc., Chicago, Illinois) and SAS 9.2 (SAS Institute,
ary, North Carolina) software.
esults
f 1,463 patients treated with primary PCI and stenting for
TEMI from 1995 to 2009, clinical follow-up was complete or
as obtained to at least 4 years in 85.0% of patients. Stent
ES for STEMI
sortium deﬁnite or probable) for bare-metal stents (BMS) and drug-eluting
ent elevation myocardial infarction (STEMI). The BMS were implanted exclu-and D
ch Con
-segm.
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33Figure 2. Landmark Analysis Showing Kaplan-Meier Estimates of VLST and Reinfarction After Primary PCI With DES and BMS for STEMI
(A) Landmark analysis of the cumulative frequency of very late stent thrombosis (VLST) (1 year) comparing BMS and DES. (B) Landmark analysis of the cumula-
tive frequency of reinfarction (1 year) comparing BMS and DES. The BMS were implanted exclusively from 1995 to 2002, whereas both stents were implanted
from 2003 to 2009. Abbreviations as in Figure 1.
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34hrombosis occurred in 107 of 1,463 patients (92 definite and
5 probable, including 13 sudden unexplained deaths 30
ays) and resulted in 23 acute deaths (21.5%) and 92 (86.0%)
einfarctions. Reinfarction occurred in 171 patients. Of these,
12 (65.5%) occurred in the target vessel, of which 92 (82.1%)
ere due to ST. Reinfarction occurred in nontarget vessels or
nknown location in 59 patients. Of the 92 reinfarctions due to
T, 63 were STEMI, including 42 of 67 (62.7%) with BMS
nd 21 of 25 (84.0%) with DES.
Of the 107 patients with ST, 38 were early (30 days), 27
ere late (31 days to 1 year), and 42 were very late (1 year).
ighty percent (80%) of patients with DES and 55% of
atients with BMS were taking clopidogrel at the time of early
T; 57% of patients with DES and 50% of patients with BMS
ere taking clopidogrel at the time of late ST; and 15% of
atients with DES and 10% of patients with BMS were taking
lopidogrel at the time of VLST. Very late stent thrombosis
esulted in 6 acute (in-hospital) deaths (14.3%), and all 42
LST resulted in reinfarction. Of the 42 reinfarctions due to
LST, 27 were STEMI. ST-segment elevation myocardial
nfarction because of VLST was more common with DES
han with BMS (11 of 13 or 84.6% vs. 16 of 29 or 55.2%, p
.08).
aseline variables comparing DES and BMS. Patients receiv-
ng BMS compared with DES were older and had more
ardiogenic shock, more 3-vessel coronary disease, and less
hrombolysis In Myocardial Infarction flow grade 2 to 3 on
nitial angiography. Patients receiving DES had more diabetes,
maller vessel size, and more anterior wall infarction (Table 1).
Table 2. Clinical Outcomes With DES Versus BMS (1995 to 2009)
DES
(n  368)
BMS
(n  1,095)
Non-landmark Kaplan-Meier analysis*
Cardiac mortality 7.7% 12.7%
Stent thrombosis (ARC deﬁnite/probable) 10.7% 6.6%
Reinfarction 16.0% 9.7%
Reinfarction target vessel 12.8% 6.5%
Reinfarction nontarget vessel or unknown 3.3% 3.4%
DES
(n  263)
BMS
(n  813)
Landmark Kaplan-Meier analysis* ( 1 yr)
Stent thrombosis (ARC deﬁnite/probable) 6.9% 1.7%
Reinfarction 9.9% 4.7%
Reinfarction target vessel 8.0% 2.1%
*Event rates are Kaplan-Meier estimates at 4.5 years. †The marked difference in p values comparin
regression and propensity analysis might be related to the propensity analysis adjustment for yearsARC Academic Research Consortium; CI confidence interval; HR hazard ratio.requency of ST. Kaplan-Meier estimates of the frequency
f ST for DES and BMS are shown in Figure 1. The
requency of ST at 1 year was similar with DES and BMS
4.0% and 5.1%, respectively). The cumulative frequency of ST
ontinued to increase out to at least 4.5 years with DES and
ut to at least 11 years with BMS but increased more after the
rst year with DES than BMS (1.9%/year vs. 0.6%/year).
andmark analysis after 1 year with Cox regression showed
hat DES compared with BMS was the strongest and only
ignificant predictor of VLST (hazard ratio [HR]: 3.79, 95%
onfidence interval [CI]: 1.64 to 8.79, p  0.002) (Fig. 2,
able 2).
requency of other cardiac events. Kaplan-Meier estimates
f other cardiac events are shown in Figure 3 and Table 2.
ardiac mortality was higher with BMS than with DES, due
o higher hospital and 30-day mortality. Reinfarction and
einfarction of the target vessel occurred more frequently after
he first year with DES than BMS. Reinfarction of the
ontarget vessel was similar with DES and BMS. Landmark
nalyses after 1 year showed that DES compared with BMS
as a significant predictor of both reinfarction (HR: 2.01, 95%
I: 1.15 to 3.50, p  0.014) and reinfarction of the target
essel (HR: 3.16, 95% CI: 1.50 to 6.64, p  0.002) (Fig. 2,
able 2).
utcomes in the DES era (2003 to 2009). We also compared
utcomes between DES and BMS in the DES era (2003 to
009) when both stents were being implanted (Fig. 4, Table 3).
he frequency of ST was high with both stent types, and there
ere no significant differences in ST and other outcomes
og-Rank
Selected Variables
Selected and Balancing
Variables
Cox Multivariable
Regression Propensity Analysis
nivariate
p Value HR (95% CI) p Value HR (95% CI) p Value
0.018 0.57 (0.36–0.90) 0.017 0.90 (0.53–1.53) 0.70†
0.070 1.31 (0.80–2.13) 0.28 1.19 (0.67–2.09) 0.55
0.017 1.36 (0.92–2.00) 0.13 1.36 (0.86–2.17) 0.19
0.012 1.38 (0.88–2.18) 0.16 1.33 (0.78–2.28) 0.30
0.815 1.16 (0.55–2.44) 0.70 1.34 (0.54–2.29) 0.53
0.001 3.79 (1.64–8.79) 0.002 3.33 (1.11–9.96) 0.032
0.003 2.01 (1.15–3.50) 0.014 2.37 (1.17–4.81) 0.016
0.0001 3.16 (1.50–6.64) 0.002 3.34 (1.26–8.86) 0.016
c mortality with drug-eluting stents (DES) and bare-metal stents (BMS) between Cox multivariate
ES were not available.L
U


g cardia
when D
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 , 2 0 1 1 Brodie et al.
J A N U A R Y 2 0 1 1 : 3 0 – 8 VLST After Primary PCI for STEMI
35Figure 3. Kaplan-Meier Estimates of Mortality and Reinfarction Rates After Primary PCI With DES and BMS for STEMI
(A) Cumulative cardiac mortality rates after primary PCI for STEMI comparing BMS and DES. (B) Cumulative reinfarction rates after primary PCI for STEMI compar-
ing BMS and DES. BMS were implanted exclusively from 1995 to 2002, whereas both stents were implanted from 2003 to 2009. Abbreviations as in Figure 1.
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36etween DES and BMS. Landmark analyses showed that the
requency of VLST (1 year), reinfarction (1 year), and
einfarction of the target vessel (1 year) were significantly
reater with DES compared with BMS before and after
djustments with Cox Regression (Fig. 4, Table 3).
iscussion
he major finding of this study is that the frequency of ST
fter primary PCI for STEMI is high with both BMS and
ES and continues to increase to at least 11 years with BMS
nd to at least 4.5 years with DES. After the first year, VLST,
einfarction, and reinfarction of the target vessel were signifi-
antly higher with DES compared with BMS. Very late stent
hrombosis resulted in reinfarction in all cases with both BMS
nd DES, but STEMI was more common with DES.
Randomized trials comparing DES with BMS with primary
CI for STEMI have shown similar rates of ST at 1 year
9–13). Data on ST rates after 1 year have been limited, but
ome data are becoming available. Two small trials, the
ESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent
n Acute Myocardial Infarction) and TYPHOON (Trial to
ssess the Use of the Cypher Stent in Acute Myocardial
nfarction Treated with Balloon Angioplasty) trials, found no
ifferences in the rates of ST between DES and BMS at 3 and
years (16,17). Another small trial, the PASSION (Paclitaxel
luting Stent Versus Conventional Stent in ST-segment
levation Myocardial Infarction) trial, found higher rates of
T with DES versus BMS at 5 years (3.6% vs. 1.7%, p 
.20), raising some concern about safety with DES (18). The
argest trial, the HORIZONS-AMI (Harmonizing Outcomes
ith Revascularization and Stents in Acute Myocardial Infarc-
ion) trial, found no differences in rates of ST between DES
nd BMS at 2 years (4.3% vs. 4.3%, p  0.98) (19). None of
hese trials found any differences in mortality or reinfarction
etween DES and BMS at late follow-up.
Our data showing that the frequency of ST with BMS
ontinues to increase to 11 years after stent implantation are
omewhat unexpected. Previous studies after elective implan-
ation of BMS have found that VLST is uncommon (20,21).
erial angiographic studies after BMS implantation have
hown that late loss is generally complete by 9 to 12 months,
fter which there is stabilization and often regression of late
oss (22). However, most of the late stent thromboses with
MS in our study had severe restenosis associated with
hrombotic occlusion, indicating that restenosis with BMS can
ccur very late after implant in some patients and can result in
LST. New strategies might be needed to deal with this
roblem of VLST with BMS.
It is not clear whether the increased frequency of VLST
ith DES compared with BMS in our study is a true difference
r might be related to selection bias. In most observational
atabases comparing DES and BMS, selection bias has fa-Figure 4. Kaplan-Meier Estimates of Cumulative ST Rates After
Primary PCI With DES and BMS for STEMI in the DES Era
(A) Cumulative frequency of ST (Academic Research Consortium deﬁnite or
probable) comparing BMS and DES. (B) Landmark analysis showing the cumu-
lative frequency of VLST (1 year) comparing BMS and DES. Both Figures 4A
and 4B show data from the DES era only (2003 to 2009) when both BMS andored DES. Bare-metal stents are generally implanted in
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37atients who are sicker, are expected to have limited life
xpectancy, are at risk for bleeding, or who are thought to be
ess compliant with medical therapies. This bias seems to be
rue in our study, because mortality was higher in patients
reated with BMS compared with DES. These differences are
ikely due to selection bias, because all the differences in
ortality occurred in the first 30 days, when the type of stent
ould not be expected to affect mortality. It is possible that
election bias involving variables affecting ST might be differ-
nt from those affecting mortality. DES might be chosen for
iabetic patients and patients with small vessels and long
esions, because of the higher risk of restenosis in these
atients. This could increase the risk of VLST with DES. We
djusted for these variables in the Cox regression analyses and
ropensity analyses, but we might not have been able to correct
or all the differences. There is also potential bias related to the
istorical time that these stents were implanted. The BMS
ere implanted from 1995 to 2009, and DES were implanted
rom 2003 to 2009. Differences in treatment protocols between
hese time periods could affect outcomes. However, one might
xpect that outcomes, including VLST, might be worse in the
arlier time period (when most BMS were implanted) when
tent deployment techniques and antiplatelet therapy were less
ptimal. We compared rates of VLST between DES and
MS in the DES era (2003 to 2009) when both types of stent
ere implanted and found similar outcomes with a higher
requency of VLST with DES. Another possibility for the
ifferences in outcomes is that the “real world” population in
ur registry might be different from the patient populations
nrolled in randomized trials. Differences in the use of dual
ntiplatelet therapy do not seem to be a likely explanation for
Table 3. Clinical Outcomes With DES Versus BMS in the DES Era (2003 to
DES
(n  368)
BMS
(n  486)
Non-landmark Kaplan-Meier analysis*
Cardiac mortality 6.2% 8.6%
Stent thrombosis (ARC deﬁnite/probable) 6.8% 5.1%
Reinfarction 11.1% 7.2%
Reinfarction target vessel 8.4% 5.4%
Reinfarction nontarget vessel or unknown 3.0% 2.1%
DES
(n  263)
BMS
(n  293)
Landmark Kaplan-Meier analysis* ( 1 yr)
Stent thrombosis (ARC deﬁnite/probable) 4.9% 1.7%
Reinfarction 8.5% 3.4%
Reinfarction target vessel 5.8% 1.7%
*Event rates are Kaplan-Meier estimates at 4.5 years.
Abbreviations as in Table 2.ifferences in VLST rates, because most patients were not Daking dual antiplatelet therapy after 1 year and the frequency
f dual antiplatelet therapy use was low in both BMS and DES
atients at the time of VLST.
There are previous data to support the position that the
requency of VLST is truly higher with DES than BMS,
ecause of differences between the 2 stent types. As stated
arlier, when DES are implanted for STEMI, there is an
ncreased incidence of late malapposition and poor healing that
ould predispose to VLST (6–9). Randomized trials with
lective stenting have shown small but significant increased
ates of VLST with DES compared with BMS (23,24). The
ASSION trial, which evaluated DES versus BMS for
TEMI and had follow-up data to 5 years, showed trends for
ncreased rates of VLST with DES (18). The relatively short
ollow-up in the HORIZONS-AMI trial and the small
ample sizes in the other randomized trials comparing DES
ith BMS with primary PCI might have so far prevented the
etection of significant differences in VLST between the 2
ypes of stents (16,17,19).
Although it is not clear whether the differences in the
requency of VLST between DES and BMS are real or are
elated to selection bias, it is clear that the frequency of ST and
ontinued late occurrence of ST after stenting for STEMI in
his “real world” STEMI population are disturbingly high for
oth BMS and DES.
tudy limitations. Our study is a single-center observational
tudy and, as discussed in the preceding text, has the potential
or selection bias that might affect outcomes. Our study is also
imited by historical time differences when DES and BMS
ere implanted, which could affect outcomes, although our
esults are similar when we analyzed the DES era when both
)
g-Rank
Value
Selected Variables
Selected and Balancing
Variables
Cox Multivariable Regression Propensity Analysis
HR (95% CI) p Value HR (95% CI) p Value
0.09 0.58 (0.40–1.14) 0.14 0.98 (0.58–1.71) 0.98
0.58 1.13 (0.65–1.98) 0.66 1.11 (0.63–1.97) 0.71
0.21 1.29 (0.82–2.04) 0.27 1.28 (0.80–2.04) 0.30
0.26 1.30 (0.77–2.21) 0.32 1.24 (0.72–2.13) 0.44
0.65 1.23 (0.51–2.98) 0.64 1.25 (0.50–3.10) 0.63
0.045 2.76 (0.98–7.78) 0.055 2.72 (0.95–7.74) 0.061
0.019 2.38 (1.13–5.04) 0.024 2.33 (1.08–4.99) 0.030
0.017 3.22 (1.17–8.89) 0.024 2.97 (1.06–8.36) 0.0392009
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pES and BMS were being implanted. We have data on dual
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38ntiplatelet therapy in patients who had ST but do not have
ata on patients without ST to assess the impact of this therapy
n outcomes. The great majority of DES implanted were
rst-generation sirolimus-eluting or paclitaxel-eluting stents,
nd our results might not apply to second-generation stents.
linical implications. Our results might have implications re-
arding the management of patients treated with primary PCI
nd stenting for STEMI. The high incidence of VLST after
tenting for STEMI with both DES and BMS should encourage
valuation of new strategies to prevent VLST, including proce-
ural techniques to optimize stent deployment (such as more
requent use of intravascular ultrasound, post-dilation, and throm-
ectomy) and longer or more intensive antiplatelet therapies. The
evelopment of newer-generation stents, including new polymers
nd bio-absorbable stents, might also help to reduce this compli-
ation. If VLST rates and reinfarction rates are truly higher with
ES compared with BMS, the benefit of reduced restenosis with
ES might not be worth the increased risk of ST and reinfarc-
ion, and BMS might be a more appropriate choice in many
atients with STEMI.
onclusions
tent thrombosis following primary PCI for STEMI is high
ith both BMS and DES and continues to increase to at
east 11 years with BMS and to at least 4.5 years with DES.
fter the first year, VLST and re-infarction were signifi-
antly higher with DES compared with BMS. New strate-
ies are needed to manage this problem.
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